12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Company News  |  Deals

Galapagos, Merck deal

Galapagos will use its SilenceSelect gene knock-down technology to discover and validate small molecule targets for Merck to treat inflammation. The companies will select 12 targets to advance, and Galapagos will...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >